X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1965) 1965
Publication (334) 334
Book Chapter (61) 61
Book Review (27) 27
Government Document (17) 17
Conference Proceeding (15) 15
Newspaper Article (13) 13
Book / eBook (9) 9
Dissertation (8) 8
Magazine Article (4) 4
Newsletter (3) 3
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1154) 1154
synthetic lethality (988) 988
humans (832) 832
animals (689) 689
cancer (491) 491
oncology (367) 367
mutation (361) 361
biochemistry & molecular biology (322) 322
cell biology (318) 318
mice (315) 315
proteins (267) 267
female (264) 264
dna repair (253) 253
research (242) 242
article (234) 234
dna damage (222) 222
cell line, tumor (216) 216
genetic aspects (205) 205
homologous recombination (205) 205
biology (198) 198
analysis (191) 191
poly polymerase (184) 184
genetics & heredity (179) 179
genes (172) 172
neoplasms - genetics (171) 171
health aspects (169) 169
apoptosis (156) 156
synthetic biology (153) 153
tumors (153) 153
genomics (150) 150
pharmacology & pharmacy (150) 150
deoxyribonucleic acid--dna (148) 148
gene expression (146) 146
genomes (146) 146
neoplasms - drug therapy (138) 138
expression (136) 136
antineoplastic agents - pharmacology (135) 135
research article (134) 134
immunology (132) 132
dna (130) 130
multidisciplinary sciences (128) 128
yeast (127) 127
genetics (125) 125
saccharomyces-cerevisiae (125) 125
saccharomyces cerevisiae - genetics (124) 124
chemotherapy (123) 123
cells (122) 122
vaccines, synthetic - immunology (122) 122
biotechnology & applied microbiology (121) 121
breast cancer (121) 121
microbiology (120) 120
male (116) 116
physiological aspects (115) 115
lethality (106) 106
medicine, research & experimental (104) 104
review (104) 104
medicine (103) 103
care and treatment (102) 102
repair (102) 102
antineoplastic agents - therapeutic use (98) 98
inhibition (98) 98
kinases (98) 98
mutations (98) 98
parp inhibitors (97) 97
identification (94) 94
rna interference (93) 93
biotechnology (92) 92
cell cycle (91) 91
molecular targeted therapy (91) 91
escherichia-coli (89) 89
inhibitors (88) 88
gene (86) 86
vaccines (86) 86
ovarian cancer (83) 83
genomic instability (82) 82
phenotype (82) 82
science (82) 82
protein (81) 81
resistance (81) 81
dna-damage (80) 80
parp inhibitor (79) 79
life sciences (78) 78
breast-cancer (77) 77
therapy (77) 77
molecular sequence data (76) 76
synthetic lethal (76) 76
toxicology (76) 76
amino acid sequence (75) 75
gene-expression (75) 75
in-vivo (74) 74
signal transduction (73) 73
mice, inbred balb c (71) 71
dna-damage response (70) 70
dna-repair (70) 70
medical research (70) 70
phosphorylation (70) 70
neoplasms - metabolism (69) 69
poly polymerase inhibitors (69) 69
saccharomyces cerevisiae - metabolism (69) 69
enzymes (68) 68
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (3) 3
Baycrest Hospital - Stacks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Online Resources - Online (1) 1
St. Michael's Hospital - Circulation Desk (1) 1
St. Michael's Hospital - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2037) 2037
French (9) 9
German (4) 4
Polish (4) 4
Japanese (2) 2
Korean (2) 2
Chinese (1) 1
Russian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science, ISSN 0036-8075, 03/2017, Volume 355, Issue 6330, pp. 1152 - 1158
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2017, Volume 23, Issue 13, pp. 3405 - 3415
Purpose: Both PARP inhibitors (PARPi) and sacituzumab govitecan (IMMU-132) are currently under clinical evaluation in triple-negative breast cancer (TNBC). We... 
POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | SACITUZUMAB GOVITECAN IMMU-132 | REPAIR | ONCOLOGY | DNA-DAMAGE | IRINOTECAN | HOMOLOGOUS RECOMBINATION | CELL-LINES | COMBINATION | PHASE-I | Piperazines - administration & dosage | Synthetic Lethal Mutations - genetics | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Gene Expression Regulation, Neoplastic | Immunoconjugates - administration & dosage | Indoles - administration & dosage | Triple Negative Breast Neoplasms - immunology | Immunoconjugates - immunology | Antibodies, Monoclonal, Humanized - administration & dosage | DNA Topoisomerases, Type I - drug effects | Triple Negative Breast Neoplasms - pathology | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | DNA Repair - drug effects | Phthalazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - immunology | Triple Negative Breast Neoplasms - therapy | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Xenograft Model Antitumor Assays | BRCA1 Protein - genetics | Drug Resistance, Neoplasm - genetics | Animals | Triple Negative Breast Neoplasms - genetics | Cell Line, Tumor | Mice | BRCA2 Protein - genetics | BRCA1 protein | DNA damage | DNA topoisomerase | Poly(ADP-ribose) polymerase | Breast cancer | Lethality | Survival | DNA repair | Bearing | Exploitation | Anticancer properties | Inhibitors | Experimental design | Cell lines | Cell cycle | Xenografts | Antitumor activity | Inhibition | Deoxyribonucleic acid--DNA | Tumors | Cancer
Journal Article
Molecular Oncology, ISSN 1574-7891, 2011, Volume 5, Issue 4, pp. 387 - 393
Journal Article
Journal Article
Science Translational Medicine, ISSN 1946-6234, 11/2016, Volume 8, Issue 365, pp. 365ec182 - 365ec182
Journal Article
Journal Article
Journal Article